A validated liquid chromatographic tandem mass spectrometric method for the determination of mirtazapine and demethylmirtazapine in human plasma: Application to a pharmacokinetic study

Analytica Chimica Acta

Volumn 514, Issue 1, 2004, Pages 15-26

  Pistos, Constantinos ^a   Koutsopoulou, Maria ^a   Panderi, Irene ^b  

^a Ind Res and Laboratory Services   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Demethylmirtazapine metabolite; Mirtazapine; Pharmacokinetics; Tandem ion trap mass spectrometry

Indexed keywords

BODY FLUIDS; CALIBRATION; EXTRACTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; MASS SPECTROMETRY;

FLOW RATES; HUMAN PLASMA; QUANTITATION;

PHARMACOKINETICS;

2 PROPANOL; ACETIC ACID ETHYL ESTER; ACETONITRILE; AMMONIUM FORMATE; BUTANE; METHYL GROUP; MIRTAZAPINE; NORMIRTAZAPINE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CALIBRATION; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; ELECTROSPRAY; FLOW RATE; HUMAN; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETER; PARTICLE SIZE; PH; PRIORITY JOURNAL; PUMP; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 2442526067     PISSN: 00032670     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.aca.2004.03.042     Document Type: Article

References (28)

1. Voortman G., Paanakker J.E. Human Psychopharm. 10:1995;S81
2. Davis R., Wilde M.I. CNS Drugs. 5:1996;389
3. Timmer C.J., Lohmann A.A.M., Mink C.P.A. Human Psychopharm. 10:1995;S97
4. Moody J.D., Freeman J.P., Fu P.P., Cerniglia C.E. Drug Metab. Dispos. 30(11):2002;1274
5. Delpressine L.P.C., Moonen M.E.G., Kaspersen F.M., Wagenaars G.N., Jacobs P.L., Timmer C.J., Paanakker J.E., van Hal H.J.M., Voortman G. Clin. Drug Invest. 15:1998;45
6. Sitsen J.M.A., Maris F.A., Timmer C.J. Eur. J. Clin. Pharmacol. 56:2000;389
7. Moore K.A., Levine B., Smith M.L., Saki A., Schames J., Smialek J.E. J. Anal. Toxicol. 23(6):1999;541
8. Anderson D.T., Fritz K.L., Muto J.J. J. Anal. Toxicol. 23(6):1999;544
9. Cohen M., Panagides J., Trimmer C.J., Huisman J.A. Eur. J. Drug Metab. Pharm. 22:1999;103
10. Richelson E. J. Clin. Psychiatry. 59(S10):1998;22
11. Timmer C.J., Paanakker J.E., de Vries M.V. Pharm. Res. 14(1):1997;98
12. Paanakker J.E., van Hal H.J.M. J. Chromatogr. 417:1987;203
13. F.A. Maris, E. Dingler, S.J. Niehues, Chromatogr. B Biomed. Sci. Appl. 721 (1999) 309.
14. Morgan P.E., Tapper J., Spencer E.P. J. Chromatogr. B. 798(2):2003;211
15. Ptacek P., Klima J., Macek J. J. Chromatogr. B. 794(2):2003;323
16. Frahnert C., Rao M.L., Grasmader K. J. Chromatogr. B. 794:2003;35
17. Romiguieres T., Pehourcq F., Matoga M., Begaud B., Jarry C. J. Chromatogr. B. 775:2002;163
18. Titier K., Castaing N., Scotto-Gommez E., Perhourcq F., Moore N., Molimard M. Ther. Drug Monit. 25:2003;581
19. Duverneuil C., de la Grandmaison Gl., de Mazancourt P., Alvarez J.C. Ther. Drug. Monit. 25:2003;565
20. Dodd S., Burrows G.D., Norman T.R. J. Chromatogr. B. 748:2000;439
21. Wynia G.S., Windhorst G., Post P.C., Maris F.A. J. Chromatogr. A. 773:1997;339
22. Mohammed J. Biomed. Chromatogr. 14:2000;422
23. W.M.A. Niessen, Liquid chromatography-mass spectrometry, Chromatographic Science Series, Vol. 79, Marcel Dekker, Inc., 1999, Chapter 13, pp. 405-459.
24. Smyth W.F. Anal. Chim. Acta. 492:2003;1
25. Mitakos A., Panderi I. Anal. Chim. Acta. 505(1):2004;107
26. ICH Topic Q2B, Pharmaeurop 8 (1996) 108.
27. Committee for proprietary medicinal products (CPMP), Note for guidance on the investigation of bioavailability and bioequivalence, 1998, London.
28. Shams M., Hiemke C., Hartter S. Ther. Drug Monit. 26(1):2004;78